Biotechnology company Purespring Therapeutics has raised about $105 million to fund its development of gene therapies for diseases of the kidney.

Purespring Therapeutics has raised $105m in a Series B funding round which will help progress its lead candidate PS-002 to ...

Medically reviewed by Kashif J. Piracha, MD Medically reviewed by Kashif J. Piracha, MD Immunoglobin A nephropathy (also ...

Immunoglobulin A nephropathy (also known as IgA nephropathy or Berger's disease) is an autoimmune disease that affects the ...

Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseasesOversubscribed financing led ...

Novartis has claimed accelerated approval from the FDA for a second indication for Fabhalta – IgA nephropathy (IgAN) – as it charts a course to blockbuster sales for the drug. The US regulator ...

Travere Therapeutics offers rare kidney disease treatments with FDA-approved Filspari. Check out why I deem TVTX stock as a ...

An Ashland resident and teacher went to Washington, D.C. to advocate for two bills that would improve the fight against rare kidney disease.

Vera Therapeutics has come a long way towards the development of Atacicept for the treatment of patients with IgAN. Read more ...

The final analysis showed treatment with sparsentan reduced the rate of decline in kidney function vs irbesartan. The Food and Drug Administration (FDA) has granted full approval to Filspari ...

According to the New Guidelines, NEFECON is the only treatment to date proven to reduce levels of pathogenic forms of IgA and IgA immune complexes. The inclusion of NEFECON in the New Guidelines Draft ...